News coverage about Sophiris Bio (NASDAQ:SPHS) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sophiris Bio earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.5733398587686 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Sophiris Bio (NASDAQ:SPHS) traded down 0.13% during midday trading on Thursday, hitting $2.24. The stock had a trading volume of 172,391 shares. The stock’s 50-day moving average is $2.23 and its 200-day moving average is $2.27. Sophiris Bio has a one year low of $1.80 and a one year high of $3.30. The company’s market cap is $67.45 million.

SPHS has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Sophiris Bio in a research note on Friday, September 15th. Maxim Group set a $6.00 price target on Sophiris Bio and gave the company a “buy” rating in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Sophiris Bio currently has a consensus rating of “Buy” and an average price target of $6.60.

COPYRIGHT VIOLATION NOTICE: “Sophiris Bio (SPHS) Receives News Impact Rating of 0.15” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Insider Buying and Selling by Quarter for Sophiris Bio (NASDAQ:SPHS)

Receive News & Stock Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related stocks with our FREE daily email newsletter.